These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9819097)

  • 1. Impact of multiple risk factors on coronary artery disease: beyond total cholesterol. Introduction.
    Gotto AM
    Am J Cardiol; 1998 Nov; 82(9A):1Q-2Q. PubMed ID: 9819097
    [No Abstract]   [Full Text] [Related]  

  • 2. Cholesterol and coronary artery disease--issues in the 1990s.
    Chia BL
    Singapore Med J; 1991 Oct; 32(5):291-4. PubMed ID: 1788566
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)?
    Sherrod JP; Krist A
    J Fam Pract; 2001 Nov; 50(11):928. PubMed ID: 11711006
    [No Abstract]   [Full Text] [Related]  

  • 4. Lipoprotein analysis.
    Colyar MR
    Adv Nurse Pract; 2002 May; 10(5):30-2. PubMed ID: 12420528
    [No Abstract]   [Full Text] [Related]  

  • 5. Dyslipidemia and coronary artery disease.
    Genest JG
    Can J Cardiol; 2000 Jan; 16 Suppl A():3A-4A. PubMed ID: 10653923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The VA HDL intervention trial: clinical implications.
    Rubins HB; Collins D; Robins SJ
    Eur Heart J; 2000 Jul; 21(14):1113-5. PubMed ID: 10924289
    [No Abstract]   [Full Text] [Related]  

  • 7. Does hypolipidemic therapy prevent coronary heart disease?
    Rifkind BM; Levy RI
    Cardiovasc Clin; 1974; 6(2):1-8. PubMed ID: 4374303
    [No Abstract]   [Full Text] [Related]  

  • 8. Aggressive medical therapy for the prevention and treatment of coronary artery disease.
    Malloy MJ; Kane JP
    Adv Intern Med; 1997; 42():1-38. PubMed ID: 9048115
    [No Abstract]   [Full Text] [Related]  

  • 9. Dyslipidemia and coronary heart disease: management issues from Indian perspective.
    Gambhir DS; Gambhir JK; Sudha R
    Indian Heart J; 2000; 52(5):515-6, 617. PubMed ID: 11256772
    [No Abstract]   [Full Text] [Related]  

  • 10. [Drug treatment of hyperlipidemia].
    Noseda G
    Ther Umsch; 1987 Aug; 44(8):578-83. PubMed ID: 3672411
    [No Abstract]   [Full Text] [Related]  

  • 11. [High cholesterol levels are discriminated by new therapeutic recommendations].
    Olsson AG
    Lakartidningen; 2000 Apr; 97(16):1995-6. PubMed ID: 10826361
    [No Abstract]   [Full Text] [Related]  

  • 12. Strategies for optimizing lipid treatment outcomes.
    Spellman CW
    J Am Osteopath Assoc; 2003 Jan; 103(1 Suppl 1):S12-5. PubMed ID: 12572625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hyperlipidemia: therapeutic principles in clinical practice].
    Müller-Wieland D; Krone W
    Med Klin (Munich); 2003 Dec; 98(12):739-43. PubMed ID: 14685674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Secondary prevention of coronary artery disease with lipid-lowering drugs].
    Delahaye F; De Gevigney G
    Ann Med Interne (Paris); 2001 Apr; 152(3):184-7. PubMed ID: 11431578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial on CHD.
    Riesen WF
    J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S1-2. PubMed ID: 9044998
    [No Abstract]   [Full Text] [Related]  

  • 16. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments for].
    de Teresa Galván E; Jiménez Navarro M
    Rev Esp Cardiol; 1996 Jul; 49(7):483-5. PubMed ID: 8754441
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of hyperlipidemia: an update.
    Keller KB; Lemberg L
    Heart Lung; 1990 May; 19(3):317-20. PubMed ID: 2341269
    [No Abstract]   [Full Text] [Related]  

  • 18. Lipids and their role in coronary heart disease: what they do and how to manage them.
    Pradka LR
    Nurs Clin North Am; 2000 Dec; 35(4):981-91. PubMed ID: 11072283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments against].
    Brotons Cuixart C; Maiques Galán A
    Rev Esp Cardiol; 1996 Jul; 49(7):486-91. PubMed ID: 8754442
    [No Abstract]   [Full Text] [Related]  

  • 20. Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype.
    Twickler TB; Dallinga-Thie GM; Cohn JS; Chapman MJ
    Circulation; 2004 Apr; 109(16):1918-25. PubMed ID: 15117861
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.